THERAPEUTIC FOCUS
RESEARCH & DEVELOPMENT
Shareholder Tools
Briefcase Printed Materials Email Alerts Download Center snapshot RSS

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

All Releases
View Summary Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee
12 Sep 2016
PDF 74.3 KB Add to Briefcase
View Summary Amarin to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
7 Sep 2016
PDF 14.8 KB Add to Briefcase
View Summary Amarin Randomizes Final Patient into REDUCE-IT Cardiovascular Outcomes Study of Vascepa
31 Aug 2016
PDF 72.2 KB Add to Briefcase
View Summary Amarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in May 2014 and November 2015
26 Aug 2016
PDF 18.2 KB Add to Briefcase
View Summary Amarin Announces Underwriters' Exercise of Option to Purchase Additional American Depositary Shares
15 Aug 2016
PDF 16.1 KB Add to Briefcase
View Summary Amarin Prices Public Offering of American Depositary Shares
11 Aug 2016
PDF 15.9 KB Add to Briefcase
View Summary Amarin Announces Proposed Public Offering of American Depositary Shares
10 Aug 2016
PDF 15.7 KB Add to Briefcase
View Summary Amarin Reports Second Quarter 2016 Financial Results and Provides Update on Operations
4 Aug 2016
PDF 100.3 KB Add to Briefcase
View Summary Amarin and FDA Reaffirm Concurrence on REDUCE-IT Through Special Protocol Assessment Agreement Amendment
4 Aug 2016
PDF 74.8 KB Add to Briefcase
View Summary Amarin to Report Second Quarter 2016 Results and Host Conference Call at 7:30 A.M. ET on August 4, 2016
28 Jul 2016
PDF 13.5 KB Add to Briefcase
View Summary Amarin to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
6 Jul 2016
PDF 11.8 KB Add to Briefcase
View Summary Amarin Appoints Michael W. Kalb Chief Financial Officer
30 Jun 2016
PDF 14.7 KB Add to Briefcase
View Summary Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Patients With Type 2 Diabetes and Persistent High Triglycerides
11 Jun 2016
PDF 74.7 KB Add to Briefcase
View Summary Vascepa(R) (Icosapent Ethyl) Data to Be Presented at American Diabetes Association's 76th Scientific Sessions
6 Jun 2016
PDF 69.1 KB Add to Briefcase
View Summary Amarin to Present at the Jefferies 2016 Global Healthcare Conference
1 Jun 2016
PDF 11.7 KB Add to Briefcase
View Summary Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa(R) (icosapent ethyl) Capsules
31 May 2016
PDF 63.7 KB Add to Briefcase
View Summary Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels
20 May 2016
PDF 72.0 KB Add to Briefcase
View Summary Vascepa(R) (icosapent ethyl) and Eicosapentaenoic Acid (EPA) Data to Be Presented at National Lipid Association 2016 Scientific Sessions
11 May 2016
PDF 103.6 KB Add to Briefcase
View Summary Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations
5 May 2016
PDF 99.3 KB Add to Briefcase
View Summary Amarin to Report First Quarter 2016 Results and Host Conference Call on May 5, 2016
28 Apr 2016
PDF 13.2 KB Add to Briefcase
Showing 1-20 of 268 Page: 1 2 3 4 5 ... 14  Next 20
Add to Briefcase = add release to Briefcase